Activated CD137 signaling regulates the expression of NFATc1 and its downstream factors in vascular smooth muscle cells through TRAF6/NF-kB p65 pathways, providing a new target for atherosclerosis therapy (56). This evidence concerns the gene TNFRSF9 and atherosclerosis.